Ryder System, Inc. logo R - Ryder System, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 1
BUY 21
HOLD 13
SELL 0
STRONG
SELL 0
| PRICE TARGET: $247.33 DETAILS
HIGH: $253.00
LOW: $236.00
MEDIAN: $250.00
CONSENSUS: $247.33
UPSIDE: 1.36%

Stock News

BioInvent Reveals Solid Data with its TNFR2 Antibody BI-1808 and KEYTRUDA(R) (pembrolizumab) in Advanced Ovarian Cancer at ASCO

BioInvent Reveals Solid Data with its TNFR2 Antibody BI-1808 and KEYTRUDA(R) (pembrolizumab) in Advanced Ovarian Cancer at ASCO

BioInvent International (STO:BINV) 24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by three the historical single agent activity of 8% in KEYNOTE-100 (2019) 56% disease control rate (DCR) in the combination arm, including multiple durable responses extending beyond 10 months with patients still on treatment The treatment exhibits a very favorable safety profile, and, in contrast to chemotherapy-based regimens, result in very low rates of safety-related treatment discontinuations A preliminary median progression-free survival (mPFS) of 10.3 months in the combination arm, based on early PFS analysis Activity observed across both high-grade serous and clear cell ovarian cancer subtypes Demonstrated robust Treg depletion, reprogramming of myeloid cells, and CD8+ T-cell activation, supporting BI-1808's differentiated mechanism and combination synergy with pembrolizumab Cohort expansion is underway, focusing on high-grade serous and clear cell subtypes, with another data readout expected in H2 2026 LUND, SE / ACCESS Newswire / May 21, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced highly promising early data from its ongoing Phase 2a clinical trial evaluating BI-1808, its monoclonal antibody targeting TNFR2, in combination with MSD's (Merck & Co., Inc., Rahway, NJ., USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of heavily pretreated patients with advanced ovarian cancer.

May 21, 2026 01:30 PM • accessnewswire.com
Theralase(R) Closes C$4.8 Million Offering

Theralase(R) Closes C$4.8 Million Offering

Toronto, Ontario--(Newsfile Corp. - May 20, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has closed its previously announced brokered private placement offering ("Brokered Offering") of 19,166,667 units ("Units") of the Company at a price of C$0.24 per Unit ("Offering Price") for gross proceeds of C$4,600,000; including, the full exercise of the over-allotment option. The Brokered Offering was led by Research Capital Corporation as sole agent and sole bookrunner ("Agent").

May 20, 2026 07:06 AM • newsfilecorp.com
Vera Quinn of Cydcor Named Entrepreneur Of the Year(R) 2026 Greater Los Angeles Finalist by EY US

Vera Quinn of Cydcor Named Entrepreneur Of the Year(R) 2026 Greater Los Angeles Finalist by EY US

EY US celebrates ambitious entrepreneurs shaping the future of business Los Angeles, California--(Newsfile Corp. - May 19, 2026) - Vera Quinn, CEO of Cydcor, has been named a finalist for the Entrepreneur Of The Year 2026 Greater Los Angeles Award by Ernst & Young LLP (EY US). Now in its 41st year, the Entrepreneur Of The Year program celebrates the bold leaders who disrupt markets through the world's most ground-breaking companies, revolutionizing industries and uplifting communities.

May 19, 2026 09:00 AM • newsfilecorp.com
GMG's THERMAL-XR(R) to be Applied Exclusively & Distributed to Global Oil and Gas/LNG Industry with Curran International

GMG's THERMAL-XR(R) to be Applied Exclusively & Distributed to Global Oil and Gas/LNG Industry with Curran International

Brisbane, Queensland, Australia--(Newsfile Corp. - May 19, 2026) - Graphene Manufacturing Group Ltd (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce the signing of a global distribution agreement with Curran International for THERMAL-XR® and for exclusive application services for the product oil and gas/LNG industry. Curran International is a global leader in providing heat transfer technologies to some of the world's largest oil and gas companies.

May 19, 2026 04:05 AM • newsfilecorp.com
Spago Nanomedical Presents Tumorad(R) Clinical Data at the International ANZSNM 2026 Conference

Spago Nanomedical Presents Tumorad(R) Clinical Data at the International ANZSNM 2026 Conference

LUND, SE / ACCESS Newswire / May 18, 2026 / Spago Nanomedical AB (publ)(STO:SPAGO.ST)(FRA:7UX.F) today announces that case findings from its ongoing Phase I/IIa clinical study Tumorad-01 have been presented at the 56th Annual Scientific Meeting of the ANZSNM, held in Canberra on 15-17 May 2026. The presentation provided an overview of the study evaluating the radiopharmaceutical drug candidate ¹⁷⁷Lu-SN201 in patients with advanced solid tumors, including case studies showing visible tumor uptake of ¹⁷⁷Lu-SN201 in two individuals with different head and neck cancers.

May 17, 2026 10:40 PM • accessnewswire.com
Caldwell Announces Relaunch of Canada's Top 40 Under 40(R) Award Program

Caldwell Announces Relaunch of Canada's Top 40 Under 40(R) Award Program

TORONTO, ON / ACCESS Newswire / May 13, 2026 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) today announced the relaunch of Canada's Top 40 Under 40® Award Program, renewing its commitment to recognizing the country's most outstanding young leaders. Caldwell is pleased to be working with Presenting Partner Tourmaline Oil Corp., National Sponsor Deloitte Canada, Travel Sponsor Air Canada, Media Sponsor Financial Post, Event Sponsor Ewing Morris & Co., and Referencing Sponsor Inline Reference Check.

May 13, 2026 05:00 AM • accessnewswire.com
Tenon(R) Medical Reports First Quarter 2026 Financial Results

Tenon(R) Medical Reports First Quarter 2026 Financial Results

~ First Quarter 2026 Revenue of $1.4 Million, an Increase of Approximately 90% Compared to Prior Year ~ ~ First Quarter Gross Profit of $0.9 Million, an Increase of Approximately 193% Compared to Prior Year ~ ~ Gross Margin Expanded Approximately 24 Percentage Points Year-Over-Year to 68.5% ~ ~ Closed $4.3 Million Senior Convertible Note Private Placement to Fund Commercial Expansion and Product Development ~ ~ Subsequent to Quarter End The Company Opened a new Center of Excellence Training Center in Tampa, FL, Along with Expansion of the Company's Sales Leadership Throughout the Eastern Region~ LOS GATOS, CA / ACCESS Newswire / May 12, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today reported financial results for the first quarter ended March 31, 2026. Financial Results and Business Updates First Quarter 2026 Results: First quarter revenue of $1.4 million, an increase of approximately 90% compared to $0.7 million in the first quarter of 2025.

May 12, 2026 12:05 PM • accessnewswire.com
BioInvent's TNFR2 Antibody BI-1808 Shows Strong Activity and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)

BioInvent's TNFR2 Antibody BI-1808 Shows Strong Activity and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)

40%   objective response rate ( ORR) as single agent in heavily pre - treated patients with advanced Cutaneous T-Cell Lymphoma (CTCL) Durable responses observed, including a complete response lasting over two years and ongoing 50% ORR in combination with KEYTRUDA® (pembrolizumab) Targeting TNFR2 drove robust immune activation, with depletion of regulatory T cells and increased CD8+ T cell infiltration in skin lesions Early immune - related skin reactions - "flares"- correlated with biological activity and immune remodeling Favorable safety profile with mostly mild to moderate treatment - related adverse events LUND, SE / ACCESS Newswire / May 12, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV)(STO:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that new clinical data from its ongoing Phase 2a trial evaluating BI-1808, its novel anti-TNFR2 monoclonal antibody, in patients with advanced CTCL will be presented at the upcoming European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden. The data underscore BI-1808's potential as both a single agent and combination therapy in this difficult-to-treat cancer with limited therapeutic options.

May 12, 2026 06:00 AM • accessnewswire.com
BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

LUND, SE / ACCESS Newswire / May 12, 2026 / BioInvent International (STO:BINV) - BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that it has been selected for a poster presentation of the BI-1206 triplet combination in relapsed/refractory non-Hodgkin's lymphoma (NHL) at the 31st European Hematology Association (EHA2026) Congress, taking place June 11-14, 2026 in Stockholm, Sweden. Poster Presentation Title: Targeting resistance to rituximab through FcγRIIB (CD32B) blockade: BI-1206 + rituximab + acalabrutinib shows powerful activity in R/R NHL Presenter: Dr. Laura Fogliatto, Hospital de Clínicas de Porto Alegre, Brazil Session Date/Time: Friday, June 12, 6:45 pm-7:45 pm CEST (12:45 pm-1:45 pm EDT) Location: EHA2026 Congress, Stockholm The presentation will summarize emerging efficacy and safety observations and mechanistic insights from the ongoing Phase 1/2 study (NCT03571568) evaluating BI-1206 in combination with rituximab and Calquence® (acalabrutinib) in patients with relapsed or refractory NHL, including follicular lymphoma.

May 12, 2026 05:45 AM • accessnewswire.com
Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

~ Patent Extends Jurisdiction and Protection Through 2042 ~ SAN DIEGO, CA / ACCESS Newswire / May 12, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics designed to minimize abuse and overdose risk, today announced that the Taiwan Intellectual Property Office issued a patent covering Ensysce's MPAR® (Multi-Pill Abuse Resistance) technology. The patent, titled "Compositions Comprising Enzyme-Cleavable Prodrugs and Controlled Release Nafamostat and Methods of Use Thereof", includes both composition-of-matter and method-of-use claims that strengthen Ensysce's intellectual property estate for its unique overdose protection platform.

May 12, 2026 04:00 AM • accessnewswire.com
Quarterly Report Q1 2026: Orviglance(R) Approaching Transformative Milestones

Quarterly Report Q1 2026: Orviglance(R) Approaching Transformative Milestones

MALMÖ, SE / ACCESS Newswire / May 12, 2026 / Ascelia Pharma AB (publ) (STO:ACE) today published its Interim Report Q1 for 2026 (January - March), which is now available on the company's website: Financial Reports - ASCELIA KEY EVENTS IN Q1 2026 Abstract with Orviglance data has been accepted for oral presentation at the annual radiology congress ESGAR 2026 Management changes: Anton Hansson starts as CFO, while Julie Waras Brogren leaves her position as Deputy CEO KEY EVENTS AFTER THE PERIOD Ascelia Pharma completes directed share issue of SEK 20 million before transaction costs FINANCIAL SUMMARY Q1 (Jan-Mar) 2026 Operating result of SEK -17.2M (SEK -20.3M) Earnings per share of SEK -0.13 (SEK -0.23) Cash flow from operations of SEK -15.9M (SEK -16.9M) Liquid assets and marketable securities of SEK 33.9M (SEK 57.3M) "Orviglance® is on track for approval on the July 3 PDUFA date. FDA's review of our New Drug Application (NDA) progressed as planned during the quarter, and we remain fully engaged in a constructive, transparent dialogue with the agency as we approach the final month of the review.

May 11, 2026 09:50 PM • accessnewswire.com
Theralase(R) Announces $4 Million Brokered LIFE Offering

Theralase(R) Announces $4 Million Brokered LIFE Offering

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has entered into an agreement with Research Capital Corporation ("RCC" or the "Agent") to act as the sole agent and sole bookrunner on a commercially reasonable "best efforts" agency basis for a brokered private placement offering ("Offering") of units of the Company ("Units") at a price of C$0.24 per Unit, to raise a minimum of C$3,000,000 and up to a maximum of C$4,000,000 in aggregate gross proceeds. Each Unit will consist of one common share of the Company ("Common Share") and one Common Share purchase warrant ("Warrant").

May 05, 2026 03:10 PM • newsfilecorp.com
Ryder CEO to Address Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference

Ryder CEO to Address Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference

MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder System, Inc. (NYSE: R) Chief Executive Officer John Diez will present a company update at the 2026 Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference. Who:  Ryder System, Inc. Chief Executive Officer John Diez What: Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference When: Tuesday, May 12, 2026 Time: 11:05 a.m. Eastern Time Webcast: To access the link to the live webcast, visit: Ryder.

May 05, 2026 02:55 AM • businesswire.com
Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update

Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update

Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancer, bacteria and viruses has released the Company's audited consolidated financial statements for the twelve-month period ended December 31st, 2025 ("Financial Statements"). Theralase® will be hosting a conference call on May 12 th at 11:00 am ET, which will include a presentation of the financial and operational results for the fiscal year ending December 31st, 2025.

May 04, 2026 01:22 PM • newsfilecorp.com
AminoQuest Labs(R) Launches New Research Platform and Expands Access to High-Purity Laboratory Peptides

AminoQuest Labs(R) Launches New Research Platform and Expands Access to High-Purity Laboratory Peptides

New York, New York--(Newsfile Corp. - May 1, 2026) - AminoQuest Labs® (https://aminoquestlabs.com), a U.S.-based supplier of research peptides, today announced the official launch of its new online platform along with expanded capabilities to support laboratories and research professionals nationwide. The newly launched website provides streamlined access to research-grade peptide compounds, enhanced product documentation, and improved ordering functionality designed for scientific and laboratory use.

May 01, 2026 07:13 PM • newsfilecorp.com

Price Targets